Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 known ✓ | P13945 | 3/20 | 0.57 |
| ▸ | ADRB2 known ✓ | P07550 | 2/20 | 0.57 |
| ▸ | ADRB1 known ✓ | P08588 | 2/20 | 0.57 |
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.57 |
| ▸ | ADRA2B known ✓ | P18089 | 2/20 | 0.57 |
| ▸ | ADRA2C known ✓ | P18825 | 2/20 | 0.57 |
| ▸ | ADRA1D known ✓ | P25100 | 2/20 | 0.57 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.57 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.57 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.57 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.57 |
| ▸ | ADRA1B known ✓ | P35368 | 1/20 | 0.57 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.47 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.47 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.45 |
| ▸ | HTR3A known ✓ | P46098 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 5/20 | 0.72 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.72 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4849450 | 0.98 | NFKB1 (0.71) | BLMPMP22NFKB1TDP1KDM4E | |
| SCHEMBL7147014 | 0.89 | NFKB1 (0.71) | BLMPMP22NFKB1TDP1KDM4E | |
| Normetanephrine SCHEMBL1168235 | 0.84 | BLM (1.00) | BLMPMP22NFKB1TDP1KDM4E | |
| Normetanephrine SCHEMBL29516838 | 0.82 | NFKB1 (1.00) | BLMPMP22NFKB1TDP1KDM4E | |
| Normetanephrine SCHEMBL4949341 | 0.82 | NFKB1 (1.00) | BLMPMP22NFKB1TDP1KDM4E | |
| Normetanephrine SCHEMBL137755 | 0.82 | NFKB1 (1.00) | BLMPMP22NFKB1TDP1KDM4E | |
| Hydrochloric Acid SCHEMBL75743 | 0.81 | BLM (0.72) | BLMPMP22NFKB1TDP1KDM4E | |
| SCHEMBL3334110 | 0.80 | NFKB1 (0.73) | BLMPMP22NFKB1TDP1KDM4E | |
| SCHEMBL4847802 | 0.80 | KDM4E (0.64) | BLMPMP22NFKB1TDP1KDM4E | |
| Hydrochloric Acid SCHEMBL9344942 | 0.80 | BLM (0.65) | BLMPMP22NFKB1TDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11752168-B2 | Methods of using cosmetic compositions comprising exopolysaccharides derived from microbial mats | LUCAS MEYER COSMETICS CANADA INC. (CA) | 2023-09-12 | — | — | US | disclosed |
| US-20210330691-A1 | METHODS OF USING COSMETIC COMPOSITIONS COMPRISING EXOPOLYSACCHARIDES DERIVED FROM MICROBIAL MATS | LUCAS MEYER COSMETICS CANADA INC (CA) | 2021-10-28 | — | — | US | disclosed |
| US-11040058-B2 | Cosmetic compositions comprising exopolysaccharides derived from microbial mats, and methods of use thereof | LUCAS MEYER COSMETICS CANADA INC. (CA) | 2021-06-22 | — | — | US | disclosed |
| US-20180256627-A1 | COSMETIC COMPOSITIONS COMPRISING EXOPOLYSACCHARIDES DERIVED FROM MICROBIAL MATS, AND METHODS OF USE THEREOF | LUCAS MEYER COSMETICS CANADA INC. (CA) | 2018-09-13 | — | — | US | disclosed |
| EP-2265249-B1 | COSMETIC COMPOSITIONS COMPRISING EXOPOLYSACCHARIDES DERIVED FROM MICROBIAL MATS, AND USE THEREOF | LUCAS MEYER COSMETICS CANADA INC (CA) | 2018-08-29 | — | — | EP | disclosed |
| EP-2164858-B1 | KGHK PEPTIDE, USE THEREOF IN COSMETIC AND COSMECEUTIC APPLICATIONS, AND COMPOSITIONS COMPRISING SAME | LUCAS MEYER COSMETICS CANADA INC (CA) | 2016-08-31 | — | — | EP | disclosed |
| US-9115176-B2 | Compounds, use thereof in cosmetic and cosmeceutic applications, and compositions comprising same | LUCAS MEYER COSMETICS CANADA INC. (CA) | 2015-08-25 | — | — | US | disclosed |
| US-8834936-B2 | Cosmetic compositions comprising asteroidea body fluid and methods of use thereof | INNOVACTIV INC. (CA) | 2014-09-16 | — | — | US | disclosed |
| US-20130190269-A1 | POLYSACCHARIDES COMPOSITIONS COMPRISING FUCANS AND GALACTANS AND THEIR USE TO REDUCE EXTRAVASATION AND INFLAMMATION | LUCAS MEYER COSMETICS CANADA INC. (CA) | 2013-07-25 | — | — | US | disclosed |
| US-8426381-B2 | Polysaccharides compositions comprising fucans and galactans and their use to reduce extravasation and inflammation | LUCAS MEYER COSMETICS CANADA INC. (CA) | 2013-04-23 | — | — | US | disclosed |
| WO-2010145008-A1 | USE OF SKIN CARE COMPOSITIONS COMPRISING LAMINARIACEA EXTRACT FOR TREATMENT OF SKIN AGING SIGNS | UNIVERSITé LAVAL (CA) | 2010-12-23 | — | — | WO | disclosed |
| US-20100310484-A1 | NOVEL PEPTIDES, USE THEREOF IN COSMETIC AND COSMECEUTIC APPLICATIONS, AND COMPOSITIONS COMPRISING SAME | INNOVACTIV INC. (CA) | 2010-12-09 | — | — | US | disclosed |
| US-20100311667-A1 | NOVEL COMPOUNDS, USE THEREOF IN COSMETIC AND COSMECEUTIC APPLICATIONS, AND COMPOSITIONS COMPRISING SAME | INNOVACTIV INC. (CA) | 2010-12-09 | — | — | US | disclosed |
| EP-2164858-A1 | NOVEL COMPOUNDS, USE THEREOF IN COSMETIC AND COSMECEUTIC APPLICATIONS, AND COMPOSITIONS COMPRISING SAME | Innovactiv Inc. (CA) | 2010-03-24 | — | — | EP | disclosed |
| WO-2010006412-A1 | COSMETIC COMPOSITIONS COMPRISING ASTEROIDEA BODY FLUID AND METHODS OF USE THEREOF | INNOVACTIV INC. (CA) | 2010-01-21 | — | — | WO | disclosed |
| WO-2009127057-A1 | COSMETIC COMPOSITIONS COMPRISING EXOPOLYSACCHARIDES DERIVED FROM MICROBIAL MATS, AND USE THEREOF | INNOVACTIV INC. (CA) | 2009-10-22 | — | — | WO | disclosed |
| US-20090215720-A1 | Polysaccharides Compositions Comprising Fucans and Galactans and their Use to Reduce Extravasation and Inflammation | LES BIOTECHNOLOGIES OCEANOVA INC. (CA) | 2009-08-27 | — | — | US | disclosed |
| WO-2009003283-A1 | NOVEL COMPOUNDS, USE THEREOF IN COSMETIC AND COSMECEUTIC APPLICATIONS, AND COMPOSITIONS COMPRISING SAME | INNOVACTIV INC. (CA) | 2009-01-08 | — | — | WO | disclosed |
| WO-2009003284-A1 | NOVEL PEPTIDES, USE THEREOF IN COSMETIC AND COSMECEUTIC APPLICATIONS, AND COMPOSITIONS COMPRISING SAME | INNOVACTIV INC. (CA) | 2009-01-08 | — | — | WO | disclosed |
| WO-2007028256-A2 | POLYSACCHARIDES COMPOSITIONS COMPRISING FUCANS AND GALACTANS AND THEIR USE TO REDUCE EXTRAVASATION AND INFLAMMATION | LES BIOTECHNOLOGIES OCEANOVA INC. (CA) | 2007-03-15 | — | — | WO | disclosed |